Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2014-02-26

FDA Approved: REYATAZ — Supplemental Application (E.R. Squibb & Sons, L.L.C.)

View source ↗

Summary

FDA approved a supplemental application for Reyataz (atazanavir) to update the labeling following submission by E.R. Squibb & Sons, L.L.C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • REYATAZ (atazanavir)

Snippet

SUPPL AP for REYATAZ (ATAZANAVIR)